Physician profile
David Ramos
NPI 1770550360
$878.08
in general payments reported to CMS, 2019-2025
14 companies · $14.73 in 2025
The $14.73 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $257 · 2021: $53.07 · 2023: $27.11 · 2024: $21.07 · 2025: $14.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.80 · Debt Forgiveness: $27.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.80 |
| Debt Forgiveness | $27.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $203.80 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $170.24 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.15 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $69.00 | 2019-2020 | |
| Pfizer INC. | $53.41 | 2019 | |
| Amarin Pharma, INC. | $53.24 | 2019-2020 | |
| Abbvie INC. | $53.07 | 2021 | |
| Allergan, INC. | $46.50 | 2020 | |
| Boston Scientific Corporation | $43.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.68 | 2019-2020 | |
| Baxter Healthcare | $27.11 | 2023 | |
| Amgen INC. | $25.34 | 2019-2020 | |
| Medtronic, INC. | $21.07 | 2024 | Plasmablade(Tm) |
| Medtronic Vascular, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.